Brainsway (NASDAQ:BWAY) Reaches New 12-Month High After Strong Earnings

Key Points

• Brainsway shares reached a new 52-week high, climbing to $17.40 after the company reported quarterly EPS of $0.14, ahead of the $0.10 analyst consensus.
• Second-quarter revenue rose 35% year over year to a record $17.1 million, surpassing expectations, while full-year 2026 revenue guidance of $68 million–$70 million exceeded the $67.8 million consensus.
• Analyst sentiment remains bullish: BTIG raised its price target from $18 to $20 with a Buy rating, and the stock carries an overall consensus rating of Buy with a $16.33 target price.

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Get Free Report)'s share price hit a new 52-week high on Thursday following a stronger than expected earnings report. The company traded as high as $17.40 and last traded at $16.60, with a volume of 622702 shares. The stock had previously closed at $14.98.

The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. Brainsway had a return on equity of 12.28% and a net margin of 15.68%.The firm had revenue of $17.11 million during the quarter, compared to analysts' expectations of $16.54 million.

Brainsway News Summary

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: BrainsWay reported record second-quarter 2026 revenue of $17.1 million, up 35% year over year and above analysts’ $16.54 million estimate. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: The company guided for fiscal 2026 revenue of $68 million to $70 million, above the $67.8 million consensus estimate, signaling continued confidence in demand and growth. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: BTIG Research raised its price target from $18 to $20 and initiated or reaffirmed a “Buy” rating. The new target implies roughly 20.5% upside from the referenced share price, providing additional support for the bullish sentiment. Brainsway Price Target Raised by BTIG
• Neutral Sentiment: The Q2 earnings call transcript may provide further detail on operating performance, commercial execution, and management’s outlook, but the available headline information is primarily consistent with the reported results. BrainsWay Q2 2026 Earnings Call Transcript
• Negative Sentiment: Adjusted or reported EPS was $0.07, below the $0.10 analyst consensus by $0.03. The earnings shortfall could limit the stock’s upside if investors place greater emphasis on profitability than revenue growth. BrainsWay Quarterly Earnings Results

Analyst Ratings Changes

BWAY has been the subject of several research analyst reports. Wall Street Zen raised shares of Brainsway from a "hold" rating to a "buy" rating in a research report on Sunday, August 2nd. HC Wainwright restated a "buy" rating and set a $14.00 price target on shares of Brainsway in a research note on Friday, July 17th. BTIG Research raised their price target on shares of Brainsway from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday. Zacks Research upgraded shares of Brainsway from a "hold" rating to a "strong-buy" rating in a research note on Monday, July 13th. Finally, New Street Research reissued a "buy" rating on shares of Brainsway in a report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $16.33.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC boosted its stake in Brainsway by 61.5% during the 1st quarter. NewEdge Advisors LLC now owns 19,828 shares of the company's stock worth $188,000 after purchasing an additional 7,549 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Brainsway in the second quarter worth about $85,000. UBS Group AG lifted its stake in shares of Brainsway by 2,028.6% in the third quarter. UBS Group AG now owns 63,878 shares of the company's stock worth $963,000 after buying an additional 60,877 shares in the last quarter. Two Sigma Investments LP boosted its position in Brainsway by 25.2% during the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company's stock worth $1,551,000 after acquiring an additional 20,706 shares during the last quarter. Finally, Bank of America Corp DE acquired a new position in Brainsway during the third quarter worth about $107,000. 30.11% of the stock is owned by hedge funds and other institutional investors.

Brainsway Stock Performance

The company has a market cap of $666.16 million, a PE ratio of 47.43 and a beta of 1.24. The firm's 50 day moving average is $15.08 and its 200-day moving average is $14.33.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway's technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company's flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source